Jonathan Leiken - Jan 30, 2023 Form 4 Insider Report for DIEBOLD NIXDORF, Inc (DBD)

Role
EVP, CLO and Secretary
Signature
Jonathan B. Leiken
Stock symbol
DBD
Transactions as of
Jan 30, 2023
Transactions value $
-$7,746
Form type
4
Date filed
2/1/2023, 05:03 PM
Previous filing
May 12, 2022
Next filing
Feb 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBD Common Shares Tax liability -$7.75K -3.37K -1.25% $2.30* 266K Jan 30, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DBD Non-Qualified Stock Option 12K Jan 30, 2023 Common Shares 12K $11.96 Direct F3
holding DBD Non-Qualified Stock Option 43.7K Jan 30, 2023 Common Shares 43.7K $4.08 Direct F3
holding DBD Non-Qualified Stock Option 24.5K Jan 30, 2023 Common Shares 24.5K $18.75 Direct F3
holding DBD Non-Qualified Stock Options 46.9K Jan 30, 2023 Common Shares 46.9K $26.60 Direct F4
holding DBD Non-Qualified Stock Option 24.6K Jan 30, 2023 Common Shares 24.6K $27.39 Direct F4
holding DBD Non-Qualified Stock Option 21.4K Jan 30, 2023 Common Shares 21.4K $32.33 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld pursuant to exercise of tax withholding right under the 2017 Equity and Performance Incentive Plan - Restricted Share Award
F2 Number includes restricted stock units.
F3 Granted under the 2017 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.
F4 Granted under the 1991 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.